BioSpace News Archive

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that all participating study sites in the Phase IIb study of pirepemat are activated and recruiting patients.

Anocca AB announces that the company has successfully raised SEK 400 million through an equity financing round led by AMF and Mellby Gård.

Cambrex celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.

AbbVie announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active systemic lupus erythematosus who continued to receive standard lupus therapies.

SNIPR Biome ApS announces positive interim clinical results from its Phase 1 clinical trial with SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.

BiomX Inc. announced that the Company will present Part 1 data from its ongoing Phase 1b/2a study evaluating the novel phage product candidate, BX004, for the treatment of chronic Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis during the Late-Breaking Science Session at 46th European Cystic Fibrosis Conference, which is being held June 7-10th, 2023, in Vienna, Austria.